Hi ShellYes sounds very promising indeed, Steven sounded very...

Hi Shell

Yes sounds very promising indeed, Steven sounded very relaxed and quietly confident.
The only problems are all good / unexpected problems, ie trial taking longer than expected
because patients are living longer and staying on the trial.(now they are good problems to have)

The standout for me was when steven stated no Australian company has ever got a oncology
drug to market by themself,
Could you only imagine the interest / spotlight we would be in if this was to happen in the future.
Then the $$$ the company would be making.
At least he has his eye on the big prize. Think and dream big as they say.

And then you throw in the platform technologies and the collaborations we have
Omnicar, Cellpryme, Penn, MD anderson, Thermofisher, Peter Mac, Miles Prince
Prescient has to be one of the most undervalued / promising companies on the ASX

Steven did mention NEU as an example if FDA approvals are given, dont know to much about them
but had a quick look and it appears they nearly 10 bagged over a 2 year period on approvals for their drugs which had
orphan drug designation.

Hopefully we are close to the bottom and start heading in the right direction regarding share price.